Prognosis of lung metastases in patients with metastatic colorectal cancer: an ARCAD meta analysis

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Henriques
Citation Annals of Oncology (2016) 27 (2): 118-128. 10.1093/annonc/mdw198
Authors J. Henriques1, D. Vernerey2, A. de Gramont3, B. Chibaudel4, E. Van Cutsem5, A. Falcone6, R..M. Goldberg7, Q. Shi8, F. Bonnetain9, E. Shmueli10
  • 1Methodology and Quality of Life Unit, Department of Oncology, EA 3181, University Hospital, Besancon, France, /
  • 2Methodological and Quality of Life in Oncology Unit, EA 3181, University Hospital of Besancon, France, /
  • 3Oncology Department, Institut Hospitalier Franco-Britannique, Levallois-Perret, France, /
  • 4Institut Franco-Britannique, Levallois-Perret, France, /
  • 5UZ Leuven-Campus Gasthuisberg, Leuven, Belgium, /
  • 6Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, /
  • 7Mayo Clinic and Mayo Cancer Center, Rochester, New York, USA, /
  • 8Mayo Clinic, Rochester, Minnesota, USA, /
  • 9University hospital of Besançon, Besançon, France, /
  • 10Sheba Medical Center, Ramat Gan, Israel, /


In metastatic colorectal cancer (mCRC) patient's outcomes could be different according to the localization of metastases and the number of sites involved with a better overall survival (OS) for those with lung metastases. We aimed to assess lung metastases prognostic for OS among mCRC patients.